TUDCA-treated chronic kidney disease-derived hMSCs improve therapeutic efficacy in ischemic disease via PrP(C)

Although autologous human mesenchymal stem cells (hMSCs) are a promising source for regenerative stem cell therapy in chronic kidney disease (CKD), the barriers associated with pathophysiological conditions limit therapeutic applicability to patients. We confirmed that level of cellular prion protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Yeo Min, Kim, SangMin, Han, Yong-Seok, Yun, Chul Won, Lee, Jun Hee, Noh, Hyunjin, Lee, Sang Hun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383184/
https://www.ncbi.nlm.nih.gov/pubmed/30785084
http://dx.doi.org/10.1016/j.redox.2019.101144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383184/
https://www.ncbi.nlm.nih.gov/pubmed/30785084
http://dx.doi.org/10.1016/j.redox.2019.101144

Ejemplares similares